DOI: 10.1111/cpr.12403

## **ORIGINAL ARTICLE**

# WILEY Cell Proliferation

# Autophagic compound database: A resource connecting autophagy-modulating compounds, their potential targets and relevant diseases

Yiqi Deng $^1$  | Lingjuan Zhu $^{1,2}$  | Haoyang Cai $^3$  | Guan Wang $^1$  | Bo Liu $^1$ 

<sup>1</sup>Department of Laboratory Medicine, Precision Medicine Center, State Key Laboratory of Biotherapy and Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Collaborative Innovation Center, Sichuan University, Chengdu, China

<sup>2</sup>School of Traditional Chinese Materia Medica, Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China

<sup>3</sup>Center of Growth, Metabolism, and Aging, Key Laboratory of Bio-Resources and Eco-Environment, College of Life Sciences, Sichuan University, Chengdu, China

#### Correspondence

Guan Wang and Bo Liu, Department of Laboratory Medicine, Precision Medicine Center, State Key Laboratory of Biotherapy and Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Collaborative Innovation Center, Sichuan University, Chengdu, China. Emails: guan8079@163.com and liubo2400@163.com

#### **Funding information**

National Key R&D Program, Grant/Award Number: 2017YFC0909302; National Natural Science Foundation of China, Grant/Award Number: 81673455 and 81402496

## Abstract

**Objectives**: Autophagy, a highly conserved lysosomal degradation process in eukaryotic cells, can digest long-lived proteins and damaged organelles through vesicular trafficking pathways. Nowadays, mechanisms of autophagy have been gradually elucidated and thus the discovery of small-molecule drugs targeting autophagy has always been drawing much attention. So far, some autophagy-related web servers have been available online to facilitate scientists to obtain the information relevant to autophagy conveniently, such as HADb, CTLPScanner, iLIR server and ncRDeathDB. However, to the best of our knowledge, there is not any web server available about the autophagymodulating compounds.

**Methods**: According to published articles, all the compounds and their relations with autophagy were anatomized. Subsequently, an online Autophagic Compound Database (ACDB) (http://www.acdbliulab.com/) was constructed, which contained information of 357 compounds with 164 corresponding signalling pathways and potential targets in different diseases.

**Results**: We achieved a great deal of information of autophagy-modulating compounds, including compounds, targets/pathways and diseases. ACDB is a valuable resource for users to access to more than 300 curated small-molecule compounds correlated with autophagy.

**Conclusions**: Autophagic compound database will facilitate to the discovery of more novel therapeutic drugs in the near future.

# 1 | INTRODUCTION

Autophagy, the well-known intracellular process of degrading or recycling damaged organelles, long-lived proteins and other cellular components, can maintain homeostasis and energy balance in cells.<sup>1</sup> This term is derived from the ancient Greek for "self-eating", named by Christian de Duve in 1963.<sup>2</sup> Depending on the transportation modes of intracellular substrates to lysosomes, autophagy can be divided into 3 identified types, microautophagy, chaperone-mediated autophagy and macroautophagy (unless stated, macroautophagy is referred to as autophagy).<sup>3</sup> Recent studies have demonstrated that dysregulation of autophagy is involved in several pathological processes, such as cancer, cardiovascular disorders, diabetes, neurodegeneration and ageing.<sup>4-8</sup> Many autophagy-related proteins have been proved as therapeutic targets such as ULK1 (Unc51-like protein kinase 1), Beclin-1, ubiquitin-like-conjugating enzyme Atg3, AMPK (adenosine 5'-monophosphate (AMP)-activated protein kinase) and so on.<sup>9-12</sup> Therefore, the regulation of autophagy will become an important therapeutic and diagnostic research field.

Yiqi Deng and Lingjuan Zhu contributed equally to this work.

# **TABLE 1** The summary of data in Autophagic Compound Database (ACDB)

Data field	Data source	Amount of data
Compounds	ChemicalBook, SciFinder, Reaxys, PubMed	357
Pathways	PubMed, text-mining	96
Potential targets	PubMed, text-mining	68
Cells types	PubMed, text-mining	443

In 2016, Yoshinori Ohsumi received the Nobel Prize in physiology or medicine for his contribution to the discovery of autophagy mechanisms. Because of the efforts of Ohsumi and other scientists, we know that autophagy controls some important physiological mechanisms. Nowadays, mechanisms of autophagy have been gradually elucidated and thus targeting autophagy for small-molecule drug discovery has been receiving a rising attention.<sup>13,14</sup> In recent years, there is growing evidence that small-molecule compounds could regulate the progression of autophagy and displayed great therapeutic potential in various diseases. Tert-butylhydroquinone (tBHQ) could protect hepatocytes against saturated fatty acids induced-lipotoxicity, via AMPKdependent autophagy induction.<sup>15</sup> Hepatocellular carcinoma has high rate of fatality; galangin could induce autophagy by activating AMPK and suppressing mTOR to function as anti-proliferation effect in vitro and in vivo.<sup>16</sup> In neurodegenerative diseases, rilmenidine administration relieved signs and decreased levels of Huntington's disease in vivo, which was partially due to its effect on enhancement of autophagy.<sup>17</sup> The neuroprotection of deferoxamine on Parkinson's disease was also contributed to activation of HIF-1 $\alpha$  and HIF-1 $\alpha$ -mediated induction of autophagy.<sup>18</sup> Moreover, Lu AE58054 and nicotinamide could directly or indirectly induce cytoprotective autophagy in Alzheimer's disease, which were undergoing clinical trials in different phases.<sup>19,20</sup>

Currently, some autophagic web servers have been available online to facilitate scientists to query autophagic resources conveniently, such as HADb (Human autophagy database), CTLPScanner (Chromothripsis-like pattern scanner), iLIR server, and ncRDeathDB (ncRNA-associated cell death database).<sup>21-24</sup> However, to the best of our knowledge, there is not any web server available about autophagymodulating compounds. Thus, in this study, an online Autophagic Compound Database (ACDB) (http://www.acdbliulab.com/) was constructed, which contained information of compounds with their targets and relevant signalling pathways in diseases.

# 2 | MATERIALS AND METHODS

## 2.1 | Web server generation

Information of ACDB web server was developed on Linux by using MySQL (version 5.1.48-log, Oracle Corporation, Redwood Shores, California, USA) database management system. ACDB web interface was built on web technologies, including PHP (versions 7.1, Zend Technologies, Cupertino, California, USA), CSS (cascading style

sheets), HTML (hypertext markup language) and JavaScript (Oracle Corporation, Redwood Shores, California, USA). Apache (version 2.4, The Apache Software Foundation, Wakefield, Massachusetts, USA) web server technology was used to develop and serve web application.

## 2.2 | Web server construction and structure

Autophagic compound database was composed of 2 primary data sheets, namely autophagy-related information (sheet 1) and compound (sheet 2). The autophagy-related information was divided into 7 parts, named No., PubMed ID, title, function, cell, disease name, pathway/potential target, respectively. We searched for all compounds and their relations with autophagy by text-mining method from related databases and published articles. The PubMed Unique Identifiers (PMIDs) and titles were collected as contents of PubMed ID and title fields. Information of autophagy-modulating compounds was inputted into the function field. The data fields such as cell, disease name, pathway/potential target were filled by authors mentioned in the article. There were 8 fields in compound sheet, including No., given name, compound name, CAS No., molecular formula, molecular weight, IUPAC name and SMILES expression. IUPAC name represented the International Union of Pure and Applied Chemistry name, and SMILES expression meant Simplified Molecular Input Line Entry Specification expression of the specific compound. "No." as the same field name of 2 sheets was performed as the connection between compound and autophagy-related information.

## 2.3 | Literature information collection

Precise information of sheet 1 was collected from related public databases and text-mining of published articles manually. PubMed ID was linked to the relevant webpage. The compound name, CAS No. and IUPAC name in compound sheet were mainly integrated and verified by Scifinder Scholar (https://scifinder.cas.org), ChemcalBook (http:// www.chemicalbook.com) and Reaxys (http://new.reaxys.com). The software ChemBioDraw Ultra 14.0.0.117 was used to draw the structure and confirm the molecular formula and weight. SMILES expressions of compounds were converted by their hand-painted structures. All the details were checked and verified by the public databases to ensure their accuracy.

## 3 | RESULTS

### 3.1 | The extracted information of ACDB

In general, we searched for all compounds and their relations with autophagy by text-mining method from published articles. Precise information of compounds was mainly integrated by Scifinder Scholar (https://scifinder.cas.org), ChemcalBook (http://www.chemicalbook. com) and Reaxys (http://new.reaxys.com). In total, 357 compounds that regulated autophagic pathways were extracted from 457 references (Table 1). Moreover, we collected and normalized the related information of these compounds, including Consummated Chemical Abstracts Service Registry Number (CAS No.), molecular formula,

Search

Ce



Keyword: Compound name(eg. LYN-1604 or UA3-02) or CAS No. (eg. 2088939-99-3) or SMILES



## (A)

Given Name	Compound Name	Functions	Cells	Diseases	Autophagy	Pubmed ID
LYN-1604	UA3-02	induce autophagy;	HEK-293T, MDA-MB-	triple negative	ULK1; target:	28553505
		associated with autophagy by	231, MDA-MB-468,	breast cancer		
		the ULK complex (ULK1-	MCF-7			
		mATG13-FIP200-ATG101)				

(B)

Given Name         LYN-1604           Compound Name         UA3-02           Molecular Formula         C33H43C12N302           Molecular Weight         584           IUPAC Name         1-(4-(2-(2, 4-dichlorophenyl)-2-(naphthalen-2- ymethoxy)ethyl)piperazin-1-yl)-2-(diisobutylamino)ethan-1-one           SMILES         C1c1=c0=c(C(0CC2=cC=c3)=c2)CN4CCN(cC(NCCC(CC)CCC)CC) -0CC4)C(c1)=C1           CAS No.         2088939-99-3	(-)	
Molecular Formula       C33H43C12N302         Molecular Weight       584         IUPAC Name       1-(4-(2-(2, 4-dichlorophenyl)-2-(naphthalen-2- ylmethoxy)ethyl)piperazin-1-yl)-2-(diisobutylamino)ethan-1-one         SNILES       C1C1=CC=C(C(0CC2=CC=C3)=C2)CN4CCN(C(CN(CC(C)C)CC(C)C)) =0)CC4)C(C1)=C1	Given Name	LYN-1604
Nolecular Weight     584       IUPAC Name     1-(4-(2-(2, 4-dichloropheny1)-2-(naphthalen-2- ylmethoxy)ethy1)piperazin-1-y1)-2-(diisobuty1amino)ethan-1-one       SNILES     C1C1=CC=C(C(OCC2=CC=C3)=C2)CN4CCN(C(CN(CC(C)C)CC(C)C)C) =0)CC4)C(C1)=C1	Compound Name	UA3-02
IUPAC Name     1-(4-(2-(2, 4-dichlorophenyl)-2-(naphthalen-2- ylmethoxy)ethyl)piperazin-1-yl)-2-(diisobutylamino)ethan-1-one       SMILES     C1C1=CC=C (C (OCC2=CC=C3) = C2)CN4CCN (C (CN (CC (C) C) CC (C) C) = 0)CC4)C (C1)=C1	Molecular Formula	C33H43C12N3O2
y1methoxy)ethy1)piperazin-1-y1)-2-(diisobuty1amino)ethan-1-one           SMILES         C1C1=CC=C (C (OCC2=CC=C3C (C=CC=C3)=C2)CN4CCN (C (CN (CC (C)C)CC (C)C))           =0)CC4)C (C1)=C1         =	Molecular Weight	584
SMILES         C1C1=CC=C (C (0CC2=CC=C3) = C2) CN4CCN (C (CN (CC (C) C) CC (C) C)           =0)CC4)C (C1)=C1	IUPAC Name	1-(4-(2-(2,4-dich1oropheny1)-2-(naphtha1en-2-
=0)CC4)C(C1)=C1		y1methoxy)ethy1)piperazin-1-y1)-2-(diisobuty1amino)ethan-1-one
	SMILES	C1C1=CC=C(C(0CC2=CC=C3C(C=CC=C3)=C2)CN4CCN(C(CN(CC(C)C)CC(C)C)
CAS No. 2088939-99-3		=0)CC4)C(C1)=C1
	CAS No.	2088939-99-3

Back

FIGURE 2 Interface of ACDB result page. A, Search results of LYN-1604; B, Information of compound LYN-1604

molecular weight and International Union of Pure and Applied Chemistry (IUPAC) name. All these information were collected from public databases or related documents. Simplified Molecular Input

Line Entry Specification (SMILES) expressions of compounds were converted by their hand-painted structures in ChemBioDraw Ultra. To obtain the functional constituents of these compounds, we manually -WILEY-Cell Proliferation

4 of 6

A. Click on the Browse menu bar Home to invoke the Search page, and input the keyword in Search Column. The keyword can be Compound name or CAS No. or SMILES expression.

Search		
	Keyword: Compound name(eg. LYN-1604 or UA3-02) or CAS No. (eg. 2088939-99-3) or SMILES	Search

B. Search result will be shown below the Search Bar.

Click Compound Name title, the database will return the detailed information of compound;
 Click Pubmed ID title, the hyperlink will transfer to the Pubmed page of the article.

Given Name	Compound Name	Functions	Cells	Diseases	Autophagy	Pubmed II
LYN-1604	UA3-02	induce autophagy;	HEK-293T, MDA-MB-	triple negative	ULK1; target:	28553505
01)		associated with autophagy by	231, MDA-MB-468,	breast cancer		02)
01)		the ULK complex (ULK1-	MCF-7			02)

C. Search result will be shown below the Search Bar.

Detailed information of compound.

	LYN-1604
Compound Name	UA3-02
Molecular Formula	C33H43C12N302
Molecular Weight	584
IUPAC Name	1-(4-(2-(2, 4-dichlorophenyl)-2-(naphthalen-2- ylmethoxy)ethyl)piperazin-1-yl)-2-(diisobutylamino)ethan-1-one
SWILES	C1C1=CC=C (C (00C2=CC=C3C (C=CC=C3)=C2) CN40CN (C (CN (CC (C) C) CC (C) C =0) CC4) C (C1)=C1
CAS No.	2088939-99-3

D. Precise information of all compounds was collected from related public databases and text-mining of published articles manually. The compound name, CAS No. and IUPAC name were mainly integrated and verified by Scifinder Scholar, ChemcalBook and Reaxys. SMILES expressions of compounds were converted by their hand-painted structures.

Please feel free to contact us if you find any problems.

#### FIGURE 3 Interface of ACDB help page

investigated related articles for data of cells, potential targeted proteins, signalling pathways and diseases.

Moreover, ACDB integrated data about the effects of compounds on autophagy and related mechanisms. Among them, 298 compounds could directly induce autophagy, and 43 compounds could inhibit autophagy. Furthermore, 16 compounds such as AU0119 (melatonin), AU0232 (chloroquine) and AU0255 (berberine) showed different functions of inducing or inhibiting autophagy in specific cells or diseases. Sixty-three compounds were discovered to have potential targets and 83 compounds were found to influence corresponding signalling pathways. AU0254 (beta-asarone) and AU0262 (AZD8055) could regulate autophagy by different pathways or receptor proteins in different diseases. For example, AU0254 functions neuroprotective effect in Parkinson's disease through JNK/Bcl-2/Beclin-1 pathway, whereas in Alzheimer's disease model, it protected cells via activation of Akt/mTOR pathway.

## 3.2 | Web server query

We generated a friendly web interface for users to easily explore the web server. Users can obtain results via fuzzy search, with compound name, CAS No. or SMILES expression as keywords (Figure 1). The result page can display the information of the compound and its connection with autophagy (Figure 2A). Users can also follow the provided hyperlinks to obtain detailed information (Figure 2B). In addition, a help hyperlink on the website is provided as an instruction to users (Figure 3). For instance, users can search by LYN-1604 (compound name), 2088939-99-3 (CAS No.) or its SMILES expression and other search-related index term to obtain the information of this compound

Cell Proliferation WILEY-

and related functions. In this search result, ULK1 is the target protein of LYN-1604 which could induce autophagy. We found that LYN-1604 has therapeutic potential to trip-negative breast cancer by targeting ULK1.<sup>9</sup> Here, cell names were also presented, such as HEK-293T, MDA-MB-231, MDA-MB-468 and MCF-7 cells. The diseases associated with the study or that authors mentioned in articles were also provided. In addition, the PMIDs and titles of all articles were provided for ACDB users to obtain detailed information.

# 4 | DISCUSSION

Autophagy refers to the natural and regulated mechanism of normal cells that disposes aged and damaged cellular components. Accumulating researches have indicated that autophagy may possess contradictory functions in certain conditions.<sup>25</sup> Depending on our data collation, small-molecule compounds could induce or inhibit autophagy via different signal pathways or targets in certain diseases.<sup>26-29</sup> Recently, plenty of researches have proved that autophagy-modulating compounds may have noteworthy therapeutic effects on cancers, neurodegenerative diseases and so on.<sup>30,31</sup> The design and development of small-molecule compounds targeting autophagy will be a promising therapeutic approach for treatment or diagnosis of diseases. However, few compounds developed as autophagic medicines have been approved for clinical use or in clinical trial. Consequently, ACDB could provide an avenue for rapidly querying and estimating autophagic-activated or -inhibited compounds for users.

In conclusion, 357 compounds, 68 potential targets, 96 signalling pathways and 443 types of cells that related to autophagy have been included in ACDB. The online interface allows users to query compounds for related targets, signalling pathways and cells and diseases. It can also help users to estimate targets and relevant pathways of synthetic or isolated compounds based on structural similarities. ACDB will be updated regularly to facilitate the research of autophagy. We believe that ACDB is a valuable resource for users to access to more than 300 curated compounds correlated to autophagy, contributing to the discovery of novel therapeutic targets in the future. Moreover, ACDB will facilitate to the discovery of more novel therapeutic drugs in the near future.

### ACKNOWLEDGEMENTS

This work was supported by grants from National Key R&D Program (2017YFC0909302), and National Natural Science Foundation of China (Grant No. 81673455 and 81402496).

### CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ORCID

Lingjuan Zhu D http://orcid.org/0000-0001-5821-1466 Bo Liu D http://orcid.org/0000-0003-3900-9486

#### REFERENCES

- Liu B, Wen X, Cheng Y. Survival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer. *Cell Death Dis.* 2013;4:e892.
- Levine B, Klionsky DJ. Autophagy wins the 2016 Nobel Prize in Physiology or Medicine: Breakthroughs in baker's yeast fuel advances in biomedical research. PNAS. 2016;114:201-205.
- 3. Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. *Cell*. 2014;157:65-75.
- Ke BW, Tian M, Li JJ, Liu B, He G. Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy. *Med Res Rev.* 2016;36:983-1035.
- Xilouri M, Brekk OR, Stefanis L. Autophagy and alpha-synuclein: relevance to parkinson's disease and related synucleopathies. *Movement Disord*. 2016;31:178-192.
- Redmann M, Darley-Usmar V, Zhang J. The role of autophagy, mitophagy and lysosomal functions in modulating bioenergetics and survival in the context of redox and proteotoxic damage: implications for neurodegenerative diseases. *Aging Dis.* 2016;7:150-162.
- Zhang C, Syed TW, Liu RJ, Yu J. Role of endoplasmic reticulum stress, autophagy, and inflammation in cardiovascular disease. Front Cardiovasc Med. 2017;4:29.
- Fetterman JL, Holbrook M, Flint N, et al. Restoration of autophagy in endothelial cells from patients with diabetes mellitus improves nitric oxide signaling. *Atherosclerosis*. 2016;247:207-217.
- Zhang L, Fu LL, Zhang SY, et al. Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo. *Chem Sci.* 2017;8:2687-2701.
- Lee JG, Wu R. Combination erlorinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer. PLoS ONE. 2012;7:e48532.
- Deng Y, Xu J, Zhang X, et al. Berberine attenuates autophagy in adipocytes by targeting becn1. *Autophagy*. 2014;10:1776-1786.
- Yang K, Xu C, Li X, Jiang H. Combination of D942 with curcumin protects cardiomyocytes from ischemic damage through promoting autophagy. J Cardiovasc Pharm. 2013;18:570-581.
- Zhang L, Li J, Ouyang L, Liu B, Cheng Y. Unravelling the roles of Atg4 proteases from autophagy modulation to targeted cancer therapy. *Cancer Lett.* 2016;373:19-26.
- Li JJ, Li SJ, Zhang L, Ouyang L, Liu B. Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose. *Oncotarget*. 2015;6:40480-40495.
- Li S, Li J, Shen C, et al. Tert-butylhydroquinone (tBHQ) protects hepatocytes against lipotoxicity via inducing autophagy independently of Nrf2 activation. *Biochem Biophys Acta*. 2014;1841:22-33.
- Zhang H, Li N, Wu J, et al. Galangin inhibits proliferation of HepG2 cells by activating AMPK via increasing the AMP/TAN ratio in a LKB1independent manner. *Eur J Pharmacol.* 2013;718:235-244.
- Rose C, Menzies FM, Renna M, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. *Hum Mol Genet*. 2010;19:2144-2153.
- Wu Y, Li X, Xie W, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. *Neurochem Int.* 2010;57: 198-205.
- Wilkinson D, Windfeld K, Colding-Jorgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebocontrolled phase 2 trial. *Lancet Neurol.* 2014;13:1092-1099.
- Liu D, Pitta M, Jiang H, et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. *Neurobiol Aging*. 2013;34:1564-1580.
- 21. Moussay E, Kaoma T, Baginska J, et al. The acquisition of resistance to  $TNF\alpha$  in breast cancer cells is associated with constitutive activation

ILEY-Proliferation

of autophagy as revealed by a transcriptome analysis using a custom microarray. *Autophagy*. 2011;7:760-770.

- 22. Yang J, Liu JX, Ouyang L, Chen Y, Liu B, Cai HY. CTLPScanner: a web server for chromothripsis-like pattern detection. *Nucleic Acids Res.* 2016;44:W252-W258.
- Kalvari I, Tsompanis S, Mulakkal NC, et al. iLIR: A web resource for prediction of Atg8-family interacting proteins. *Autophagy*. 2014;10:913-925.
- 24. Wu D, Huang Y, Kang JJ, et al. ncRDeathDB: a comprehensive bioinformatics resource for deciphering network organization of the ncRNA-mediated cell death system. *Autophagy*. 2015;11: 1917-1926.
- Cheng Y, Ren X, Hait WN, Yang JM. Therapeutic targeting of autophagy in disease: biology and pharmacology. *Pharmacol Rev.* 2013;65:1162-1197.
- Xue Z, Guo Y, Zhang S, et al. Beta-asarone attenuates amyloid beta-induced autophagy via Akt/mTOR pathway in PC12 cells. Eur J Pharmacol. 2014;741:195-204.
- Zhang S, Gui XH, Huang LP, et al. Neuroprotective Effects of β-Asarone Against 6-Hydroxy Dopamine-Induced Parkinsonism via JNK/Bcl-2/Beclin-1 Pathway. *Mol Neurobiol*. 2016;53:83-94.

- Li Q, Song XM, Ji YY, Jiang H, Xu LG. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. *Biochem Bioph Res Co.* 2013;440:701-706.
- Hu M, Huang H, Zhao R, et al. AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma. *Oncol Rep.* 2014;31:649-656.
- Sarkar S, Rubinsztein DC. Small molecule enhancers of autophagy for neurodegenerative diseases. *Mol BioSyst.* 2008;4:895-901.
- Tong XP, Chen Y, Zhang SY, et al. Key autophagic targets and relevant small-molecule compounds in cancer therapy. *Cell Prolif.* 2015;48:7-16.

How to cite this article: Deng Y, Zhu L, Cai H, Wang G, Liu B. Autophagic compound database: A resource connecting autophagy-modulating compounds, their potential targets and relevant diseases. *Cell Prolif.* 2018;51:e12403. <u>https://doi.org/</u> 10.1111/cpr.12403